Immunization against Leishmania major infection using LACK- and IL-12-expressing lactococcus lactis induces delay in footpad swelling

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Hugentobler, Felix ^a   Yam, Karen K ^a   Gillard, Joshua ^a   Mahbuba, Raya ^a   Olivier, Martin ^a,b,c   Cousineau, Benoit ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c Department of Microbiology and Immunology   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; INTERLEUKIN 12; PROTEIN LACK; UNCLASSIFIED DRUG; LACK ANTIGEN, LEISHMANIA; PARASITE ANTIGEN; PROTOZOAL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FOOT PAD; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; LACTOCOCCUS LACTIS; LEISHMANIASIS; MOUSE; NONHUMAN; PARASITE LOAD; PLASMID; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL THERAPY; GENETICS; IMMUNOLOGY; LEISHMANIA MAJOR; METHODOLOGY; SKIN LEISHMANIASIS; T LYMPHOCYTE; TH1 CELL; TRANSGENIC ORGANISM;

ANIMALS; ANTIGENS, PROTOZOAN; BIOLOGICAL THERAPY; IMMUNIZATION; INTERLEUKIN-12; LACTOCOCCUS LACTIS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; ORGANISMS, GENETICALLY MODIFIED; PROTOZOAN PROTEINS; T-LYMPHOCYTES; TH1 CELLS;

EID: 84856770193     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030945     Document Type: Article

References (46)

1. Ameen M, (2010) Cutaneous leishmaniasis: advances in disease pathogenesis, diagnostics and therapeutics. Clin Exp Dermatol 35: 699-705.
2. Ait-Oudhia K, Gazanion E, Vergnes B, Oury B, Sereno D, (2011) Leishmania antimony resistance: what we know what we can learn from the field. Parasitol Res.
3. Sacks D, Noben-Trauth N, (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2: 845-858.
4. Mougneau E, Bihl F, Glaichenhaus N, (2011) Cell biology and immunology of Leishmania. Immunol Rev 240: 286-296.
5. Belkaid Y, von Stebut E, Mendez S, Lira R, Caler E, et al. (2002) CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 168: 3992-4000.
6. Scharton TM, Scott P, (1993) Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med 178: 567-577.
7. Kedzierski L, (2010) Leishmaniasis Vaccine: Where are We Today? J Glob Infect Dis 2: 177-185.
8. Mougneau E, Altare F, Wakil AE, Zheng S, Coppola T, et al. (1995) Expression cloning of a protective Leishmania antigen. Science 268: 563-566.
9. Kelly BL, Stetson DB, Locksley RM, (2003) Leishmania major LACK antigen is required for efficient vertebrate parasitization. J Exp Med 198: 1689-1698.
10. Gonzalez-Aseguinolaza G, Taladriz S, Marquet A, Larraga V, (1999) Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum. Eur J Biochem 259: 909-916.
11. Gonzalo RM, Rodriguez JR, Rodriguez D, Gonzalez-Aseguinolaza G, Larraga, et al. (2001) Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36. Microbes Infect 3: 701-711.
12. Dondji B, Perez-Jimenez E, Goldsmith-Pestana K, Esteban M, McMahon-Pratt D, (2005) Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect Immun 73: 5286-5289.
13. Tapia E, Perez-Jimenez E, Lopez-Fuertes L, Gonzalo R, Gherardi MM, et al. (2003) The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK. Microbes Infect 5: 73-84.
14. Pinto EF, Pinheiro RO, Rayol A, Larraga V, Rossi-Bergmann B, (2004) Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK. Infect Immun 72: 4521-4527.
15. Soussi N, Milon G, Colle JH, Mougneau E, Glaichenhaus N, et al. (2000) Listeria monocytogenes as a short-lived delivery system for the induction of type 1 cell-mediated immunity against the p36/LACK antigen of Leishmania major. Infect Immun 68: 1498-1506.
16. Soussi N, Saklani-Jusforgues H, Colle JH, Milon G, Glaichenhaus N, et al. (2002) Effect of intragastric and intraperitoneal immunisation with attenuated and wild-type LACK-expressing Listeria monocytogenes on control of murine Leishmania major infection. Vaccine 20: 2702-2712.
17. Lange UG, Mastroeni P, Blackwell JM, Stober CB, (2004) DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice. Infect Immun 72: 4924-4928.
18. Casalta E, Montel MC, (2008) Safety assessment of dairy microorganisms: the Lactococcus genus. Int J Food Microbiol 126: 271-273.
19. US FDA, (1995) Aminopeptidase enzyme preparation derived from Lactococcus lactis. [21CFR184.1985]. U.S. Food and Drug Administration: Code of Federal Regulations, Title 21- Food and Drugs; Chapter I- Food and Drug Administration, Department of Health and Human Services; Subchapter B- Food for human consumption; Part 184- Direct food substances affirmed as Generally Recognized as Safe.
20. Bahey-El-Din M, Gahan CG, Griffin BT, (2010) Lactococcus lactis as a cell factory for delivery of therapeutic proteins. Curr Gene Ther 10: 34-45.
21. Grangette C, Muller-Alouf H, Geoffroy M, Goudercourt D, Turneer M, et al. (2002) Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria: impact of strain viability and in vivo persistence. Vaccine 20: 3304-3309.
22. Robinson K, Chamberlain LM, Schofield KM, Wells JM, Le Page RW, (1997) Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat Biotechnol 15: 653-657.
23. Robinson K, Chamberlain LM, Lopez MC, Rush CM, Marcotte H, et al. (2004) Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C. Infection & Immunity 72: 2753-2761.
24. Wells JM, Mercenier A, (2008) Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 6: 349-362.
25. Rottiers P, De Smedt T, Steidler L, (2009) Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis. Int Rev Immunol 28: 465-486.
26. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, et al. (2006) A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 4: 754-759.
27. Villatoro-Hernandez J, Montes-de-Oca-Luna R, Kuipers OP, (2011) Targeting diseases with genetically engineered Lactococcus lactis and its course towards medical translation. Expert Opin Biol Ther.
28. Yam KK, Pouliot P, N'diaye MM, Fournier S, Olivier M, et al. (2008) Innate inflammatory responses to the Gram-positive bacterium Lactococcus lactis. Vaccine 26: 2689-2699.
29. Yam KK, Hugentobler F, Pouliot P, Stern AM, Lalande JD, et al. (2011) Generation and evaluation of A2-expressing Lactococcus lactis live vaccines against Leishmania donovani in BALB/c mice. J Med Microbiol.
30. Trinchieri G, (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146.
31. Mierau I, Kleerebezem M, (2005) 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol 68: 705-717.
32. Melby PC, Yang J, Zhao W, Perez LE, Cheng J, (2001) Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 69: 4719-4725.
33. Le Loir Y, Gruss A, Ehrlich SD, Langella P, (1998) A nine-residue synthetic propeptide enhances secretion efficiency of heterologous proteins in Lactococcus lactis. J Bacteriol 180: 1895-1903.
34. Ribeiro LA, Azevedo V, Le Loir Y, Oliveira SC, Dieye Y, et al. (2002) Production and targeting of the Brucella abortus antigen L7/L12 in Lactococcus lactis: a first step towards food-grade live vaccines against brucellosis. Appl Environ Microbiol 68: 910-916.
35. Bermudez-Humaran LG, Langella P, Cortes-Perez NG, Gruss A, Tamez-Guerra RS, et al. (2003) Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infection & Immunity 71: 1887-1896.
36. Mills DA, Choi CK, Dunny GM, McKay LL, (1994) Genetic analysis of regions of the Lactococcus lactis subsp. lactis plasmid pRS01 involved in conjugative transfer. Appl Environ Microbiol 60: 4413-4420.
37. Prina E, Lang T, Glaichenhaus N, Antoine JC, (1996) Presentation of the protective parasite antigen LACK by Leishmania-infected macrophages. J Immunol 156: 4318-4327.
38. Abu-Dayyeh I, Shio MT, Sato S, Akira S, Cousineau B, et al. (2008) Leishmania-induced IRAK-1 inactivation is mediated by SHP-1 interacting with an evolutionarily conserved KTIM motif. PLoS Negl Trop Dis 2: e305.
39. Kobets T, Badalova J, Grekov I, Havelkova H, Svobodova M, et al. (2010) Leishmania parasite detection and quantification using PCR-ELISA. Nat Protoc 5: 1074-1080.
40. Sriraman K, Jayaraman G, (2008) HtrA is essential for efficient secretion of recombinant proteins by Lactococcus lactis. Appl Environ Microbiol 74: 7442-7446.
41. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850.
42. Stober CB, Lange UG, Roberts MT, Alcami A, Blackwell JM, (2005) IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. J Immunol 175: 2517-2524.
43. Norton PM, Brown HW, Wells JM, Macpherson AM, Wilson PW, et al. (1996) Factors affecting the immunogenicity of tetanus toxin fragment C expressed in Lactococcus lactis. FEMS Immunol Med Microbiol 14: 167-177.
44. Kane MM, Mosser DM, (2001) The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 166: 1141-1147.
45. Miles SA, Conrad SM, Alves RG, Jeronimo SM, Mosser DM, (2005) A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med 201: 747-754.
46. Noben-Trauth N, Lira R, Nagase H, Paul WE, Sacks DL, (2003) The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J Immunol 170: 5152-5158.